Abstract
Establishment of chimeric antibodies and humanized antibodies has solved the problem of antigenicity of mouse monoclonal antibodies and efficacy of these antibodies has been demonstrated in a number of clinical trials. Novel antibody drugs named Rituxan and Herceptin for the indication of non-Hodgkin's lymphoma and breast cancer respectively have been evaluated as innovative drugs in oncology area. In this article, antibody technology as the basis of antibody drugs, anti-tumor mechanism of antibody, target antigens and current status of clinical trial of antibodies are introduced.
